Approximately 15 ~ 20% of non-squamous NSCLC patients present with an EGFR mutation and routine testing of EGFR mutation is recommended in metastatic NSCLC with non-squamous histology [226, 227]. Here, EGFR is linked to non-small cell lung carcinoma.